An antibody that binds a CD8α hinge region, wherein the antibody is capable of binding to a functional exogenous receptor, and wherein the functional exogenous receptor comprises an extracellular domain, the CD8α hinge region, a transmembrane domain, and an intracellular signaling domain.

Means that enables monitoring of an anticancer effect of an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint is disclosed. The method for testing a therapeutic effect of a cancer therapy of the present invention is a method for testing a therapeutic effect of an anticancer drug comprising as an effective ingredient an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint, which method comprises investigation of expression of (1) at least one immune checkpoint receptor, (2) CD8, and (3) at least one cell surface molecule selected from the group consisting of CD44 and CD45RO, on T cells using a sample derived from a patient who received the anticancer drug. Induction of a T cell population which is positive for the immune checkpoint molecule (1) and positive for CD8, and which shows high expression of CD44 and/or high expression of CD45RO, indicates that said anticancer drug is producing a therapeutic effect in said patient.

Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.

Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent. In certain embodiments, the method includes determining, by immunohistochemistry, the number of PD-L1 positive malignant cells in a tumor tissue section as well as the number of infiltrating non-malignant cells and/or non-malignant cells of the stromal interface area. The infiltrating non-malignant cells and/or non-malignant cells of the stromal interface area are positive for a marker selected from PD-L1, CD8, CD68, and any combination thereof. Compositions and kits or performing the disclosed methods are also provided.

The present invention relates to Mycobacterium tuberculosis (M tuberculosis) proteins and immunologically active fragments (peptides or mimotope peptides) thereof. In particular, the invention relates to a group of M. tuberculosis proteins and peptides thereof that are both highly antigenic and characteristic of clinical strains of M. tuberculosis. Accordingly, the further relates to the use of these M. tuberculosis proteins or peptides in diagnosing, treating or preventing M. tuberculosis complex infection.

The present invention is based on the identification, of compositions and methods for the identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators.

The present invention relates to the field of treatment efficacy prediction in patients with malignant diseases. More precisely, this invention relates to the prediction of the efficacy of a treatment in cancer patients, based on the precise quantification of several biological markers that are related to the innate and adaptive immune response of said patient against said cancer.

Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.

Provided herein are methods and compositions for single cell characterization using affinity-oligonucleotide conjugates. Provided herein are methods and compositions for single cell characterization using tetramer-oligonucleotide conjugates.

The present application provides stable peptide-based CD8 capture agents and methods of use as detection agents. The application further provides methods of manufacturing CD8 capture agents.